AntiagingAtlanta

 
Testosterone Replacement Therapy TRT Hormone
     
 

by Dr. Randy Smith of Antiaging Atlanta

   

 

Erythrocyctosis Following Testosterone Therapy TRT - Side Effect Easily Managed by Therapeutic Phlebotomy and Monitoring of Hct / Hg

 

2017 May 16. pii: S2050-0521(17)30041-0. doi: 10.1016/j.sxmr.2017.04.001. [Epub ahead of print]

Erythrocytosis Following Testosterone Therapy.

Abstract

INTRODUCTION:

A rapid increase in awareness of androgen deficiency has led to substantial increases in prescribing of testosterone therapy (TTh), with benefits of improvements in mood, libido, bone density, muscle mass, body composition, energy, and cognition. However, TTh can be limited by its side effects, particularly erythrocytosis. This review examines the literature on testosterone-induced erythrocytosis and polycythemia.

AIM:

To review the available literature on testosterone-induced erythrocytosis, discuss possible mechanisms for pathophysiology, determine the significance of formulation, and elucidate potential thromboembolic risk.

METHODS:

A literature review was performed using PubMed for articles addressing TTh, erythrocytosis, and polycythemia.

MAIN OUTCOME MEASURES:

Mechanism, pharmacologic contribution, and risk of testosterone-induced erythrocytosis.

RESULTS:

For men undergoing TTh, the risk of developing erythrocytosis compared with controls is well established, with short-acting injectable formulations having the highest associated incidence. Potential mechanisms explaining the relation between TTh and erythrocytosis include the role of hepcidin, iron sequestration and turnover, erythropoietin production, bone marrow stimulation, and genetic factors. High blood viscosity increases the risk for potential vascular complications involving the coronary, cerebrovascular, and peripheral vascular circulations, although there is limited evidence supporting a relation between TTh and vascular complications.

CONCLUSION:

Short-acting injectable testosterone is associated with greater risk of erythrocytosis compared with other formulations. The mechanism of the pathophysiology and its role on thromboembolic events remain unclear, although some data support an increased risk of cardiovascular events resulting from testosterone-induced erythrocytosis. Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis Following Testosterone Therapy. Sex Med Rev 2017;X:XXX-XXX.

Copyright © 2017 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

KEYWORDS:

Erythrocytosis; Hormone Replacement; Hypogonadism; Polycythemia; Testosterone

PMID:
28526632
PMCID:
PMC5690890
[Available on 2018-11-16]
DOI:
10.1016/j.sxmr.2017.04.001
     
  Personal Message from Dr. Smith
     
   

My primary goal at AntiagingAtlanta is to enhance your quality of life through providing a comprehensive approach to antiaging medicine.

I am committed to providing you with the best Antiaging Medicine program available.

Call me today and schedule your Antiaging Medicine evaluation.

Sincerely,

Dr. Randy Smith

     
     

 

Antiaging Atlanta
12600 Deerfield Parkway
Suite 100
Alpharetta, Georgia 30004

Phone: 678-566-3602

Call today today and speak with Dr. Smith to schedule your personal Agntiaging Medicine evaluation.

www.antiagingatlanta.com

Getting Started

To unsubscribe to our newsletter email Dr. Smith at:

Dr. Smith